摘要
目的研究多奈哌齐治疗我国轻中度阿尔茨海默病(AD)患者的疗效和安全性.方法将48例轻中度AD患者随机均分为两组,用多奈吸哌齐和卡巴拉汀治疗16周.采用简易精神状态量表(MMSE)、Blessed-Roth量表和总体衰退量表(GDS)评定疗效.安全性检查包括生命体征,实验室及心电图检查,每4周1次.结果两组治疗前后MMSE,GDS和Blessed-Roth评分均有显著改善(P＜0.05).但两组治疗前后相关量表总分差值的t检验均无显著意义(P＞0.05).两组治疗前后Blessed-Roth各亚项分数差值比较无显著性(P＞0.05).不良反应为胃肠道反应,发生率在15.0%～29.5%之间,以卡巴拉汀组多见.结论多奈吸哌齐和卡巴拉汀可显著改善AD患者的认知功能、痴呆程度和日常生活能力,疗效相当,较为安全,耐受性较好.
Objectives: To study the efficacy and safety of donepezil in the treatment of patients with mild to moderate Alzheimer′s disease (AD) in our country. Methods: 48 cases with mild to moderate AD were divided into two groups randomly and treated bydonepezil and rivastigmine, respectively. Mini Mental State Examination (MMSE), Blessed-Routh Rating Scale (BRRS) and Global Deterioration Scale (GDS) were evaluated for efficacy, Vital signs, ECG and laboratorial tests were measured every 4 weeks for safety. Results: The scores of MMSE, GDS and BRRS in the two groups were improved greatly (P<0.05). But the difference of those scores between two groups at both baseline and end-point was not significant (P>0.05). Gastrointestinal reaction as adverse event occurred in 13.6%~29.5% patients in two groups and more commonly in rivastigmine treatment. Conclusion: Donepezil and rivastigmine both similarly improve cognitive ability, dementia degree and daily living ability in AD patients in our country and have generally well toleration and safety.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2005年第5期649-653,共5页
China Journal of Modern Medicine
